D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Immunology D-index 53 Citations 11,930 143 World Ranking 2402 National Ranking 1163
Medicine D-index 71 Citations 17,417 249 World Ranking 14853 National Ranking 7672

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Immune system

Craig L. Slingluff spends much of his time researching Melanoma, Immunology, CTL*, Epitope and Melanoma Vaccine. His Melanoma study incorporates themes from Cell culture, Cell growth, Tumor microenvironment, Tyrosinase Peptide and B cell. His work is connected to Adjuvant, Immunogenicity, Immune system, Antigen and Immunotherapy, as a part of Immunology.

His CTL* study is concerned with the field of Cytotoxic T cell as a whole. His work deals with themes such as T cell, Molecular biology, Major histocompatibility complex and Peptide, which intersect with Epitope. His Melanoma Vaccine research includes themes of ELISPOT and Tetanus, Vaccination.

His most cited work include:

  • Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines (794 citations)
  • Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment (614 citations)
  • Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. (589 citations)

What are the main themes of his work throughout his whole career to date?

Craig L. Slingluff mainly investigates Melanoma, Immunology, Immune system, Cancer research and Immunotherapy. His research in Melanoma focuses on subjects like Biopsy, which are connected to Sentinel lymph node and Sentinel node. In Immunology, Craig L. Slingluff works on issues like Cytotoxic T cell, which are connected to Major histocompatibility complex.

His Cancer research study integrates concerns from other disciplines, such as Cancer cell, Tumor-infiltrating lymphocytes and CXCR3. Within one scientific family, Craig L. Slingluff focuses on topics pertaining to Oncology under Immunotherapy, and may sometimes address concerns connected to Advanced melanoma, Pembrolizumab and Pancreatic cancer. His work carried out in the field of CTL* brings together such families of science as Epitope and Peptide.

He most often published in these fields:

  • Melanoma (48.44%)
  • Immunology (35.64%)
  • Immune system (23.88%)

What were the highlights of his more recent work (between 2017-2021)?

  • Melanoma (48.44%)
  • Cancer research (21.80%)
  • Immune system (23.88%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Melanoma, Cancer research, Immune system, Immunotherapy and Internal medicine. His Melanoma research incorporates themes from Immunohistochemistry, Metastasis, Radiology and Melanoma Vaccine. His research in Cancer research intersects with topics in Tumor-infiltrating lymphocytes, Wnt signaling pathway, Infiltration and Antigen.

Immune system is a primary field of his research addressed under Immunology. The concepts of his Immunotherapy study are interwoven with issues in Lymph node, Clinical trial and Medical physics. Craig L. Slingluff has included themes like Immunomodulation Therapy and Oncology in his Internal medicine study.

Between 2017 and 2021, his most popular works were:

  • Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. (59 citations)
  • Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 + T cells (38 citations)
  • An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (28 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Immune system

Craig L. Slingluff spends much of his time researching Cancer research, Melanoma, Immune system, Cytotoxic T cell and CD8. His Cancer research study combines topics in areas such as Cancer, Infiltration, Lymph, Adoptive cell transfer and Ipilimumab. His Melanoma research is multidisciplinary, incorporating elements of Internal medicine, Clinical trial, Oncology and Immunotherapy.

His Internal medicine research includes elements of Review article and Antigen. His Immune system study contributes to a more complete understanding of Immunology. His study in Cytotoxic T cell is interdisciplinary in nature, drawing from both Acquired immune system, T cell, Desmoplastic melanoma, Pathology and Effector.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase

David H. Munn;Madhav D. Sharma;Jeffrey R. Lee;Kanchan G. Jhaver.
Science (2002)

1229 Citations

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines

Andrea L. Cox;Jonathan Skipper;Ye Chen;Robert A. Henderson.
Science (1994)

1108 Citations

Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

Helena Harlin;Yuru Meng;Amy C. Peterson;Yuanyuan Zha.
Cancer Research (2009)

751 Citations

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Nadeem Riaz;Jonathan J. Havel;Vladimir Makarov;Alexis Desrichard.
Cell (2017)

668 Citations

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

J C Skipper;R C Hendrickson;P H Gulden;V Brichard.
Journal of Experimental Medicine (1996)

478 Citations

Immunotype and Immunohistologic Characteristics of Tumor Infiltrating Immune Cells are Associated with Clinical Outcome in Metastatic Melanoma

Gulsun Erdag;Jochen T. Schaefer;Jochen T. Schaefer;Mark E. Smolkin;Donna H. Deacon.
Cancer Research (2012)

455 Citations

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

Craig L. Slingluff;Gina R. Petroni;Galina V. Yamshchikov;Donna L. Barnd.
Journal of Clinical Oncology (2003)

447 Citations

Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-α

Thomas Tüting;Cara C. Wilson;Dina M. Martin;Yvette L. Kasamon.
Journal of Immunology (1998)

329 Citations

Phase I Trial of a Melanoma Vaccine with gp100280–288 Peptide and Tetanus Helper Peptide in Adjuvant Immunologic and Clinical Outcomes

Craig L. Slingluff;Galina Yamshchikov;Patrice Neese;Holly Galavotti.
Clinical Cancer Research (2001)

316 Citations

The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

T L Darrow;C L Slingluff;H F Seigler.
Journal of Immunology (1989)

315 Citations

Best Scientists Citing Craig L. Slingluff

Francesco M. Marincola

Francesco M. Marincola

National Institutes of Health

Publications: 80

John F. Thompson

John F. Thompson

University of Sydney

Publications: 74

Steven A. Rosenberg

Steven A. Rosenberg

National Institutes of Health

Publications: 70

Thomas F. Gajewski

Thomas F. Gajewski

University of Chicago

Publications: 66

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 64

John M. Kirkwood

John M. Kirkwood

University of Pittsburgh

Publications: 60

Victor H. Engelhard

Victor H. Engelhard

University of Virginia

Publications: 59

Lisa H. Butterfield

Lisa H. Butterfield

University of California, San Francisco

Publications: 59

Walter J. Storkus

Walter J. Storkus

University of Pittsburgh

Publications: 53

Merrick I. Ross

Merrick I. Ross

The University of Texas MD Anderson Cancer Center

Publications: 50

Vernon K. Sondak

Vernon K. Sondak

University of South Florida

Publications: 48

Laurence Zitvogel

Laurence Zitvogel

Institut Gustave Roussy

Publications: 47

Ena Wang

Ena Wang

Nurix Therapeutics

Publications: 47

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 46

Thierry Boon

Thierry Boon

Ludwig Cancer Research

Publications: 46

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.